New scan could reveal breast cancer type without a needle
NCT ID NCT05923177
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested a new radioactive imaging agent, called [123I] I-(HE)3-G3, to see if it can safely detect HER2 protein in breast cancer tumors using SPECT scans. Ten people with either HER2-positive or HER2-negative breast cancer received one injection and were scanned over 48 hours. The goal was to measure how the agent spreads in the body and whether it can tell HER2-positive from HER2-negative tumors, potentially offering a non-invasive way to determine cancer type.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iodine-123-labelled designed ankyrin repeat proteins HE3-G3 ([123I] I-(HE)3-G3)
What this could lead to
If successful, this could lead to a new imaging method to see HER2 status in breast cancer without needing a biopsy.
What could go wrong
This is a very early, small Phase 1 study with only 10 people. It only tests if the imaging agent is safe and can be seen on scans, not if it improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia